Immunex Corporation

Amgen Inc.

John Ernest Sims

Steven K Dower

Teresa L Born

Dirk E Smith

Carl J March

David L Urdal

Patricia Parnet

Stewart D Lyman

Blair R Renshaw

David J Cosman

Bruce A Mosley

Stephen D Lupton

Hilary Jean McKenna

Allison P Armstrong

Timothy A Bird

Dirk M Anderson

Randal Robert Ketchem

G Duke Virca

Jennifer E Towne

Christopher Gabel

Craig A Smith

Jeffrey T McGrew

Marek Z Kubin

Alf D Larsen

Benson M Curtis

Louise Conroy

Duncan James Cochrane

Hans-Juergen Gruss

Jennifer L Slack

Margit Gayle

Hilary J McKenna

Luke A J O'Neill

Allison P Jacob

Duncan Cochrane

Blair Robert Renshaw

Hilary Mckenna

The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.

Antibodies that inhibit TSLP activity

The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

IL-1F8 polypeptides

Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.

Methods of treatment using IL-18 receptor antigen binding proteins

IL-1F5 polypeptides

IL-18 receptor antigen binding proteins

A novel polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18.

Host cells expressing IL-18 receptors

IL-1F6 polypeptides

2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.

Methods of treating inflammatory disorders of the lungs

The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.

ACPL-related assays

DNA encoding SIGIRR polypeptides and methods for using the encoded polypeptides are disclosed.

Antibodies to SIGIRR

IL-18 receptors

The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.

Human IL-1 epsilon DNA and polypeptides

Growing community of inventors

Seattle, WA, United States of America

John Ernest Sims